We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
Read MoreHide Full Article
Key Takeaways
WST's HVP Components sales rose 19.4%, while HVP Delivery Devices sales increased 29.6%.
West raised 2026 organic sales growth guidance to 10%-11% and adjusted EPS to $8.85-$9.05.
WST trades at 37.1X forward earnings, more than double its sub-industry's 17.8X multiple.
West Pharmaceutical Services, Inc. (WST - Free Report) shares have gained 17.2% in the past three months, ahead of the Zacks Medical sector's 18.9% rise and the S&P 500's 2% advance. The move reflects improving operating momentum, but valuation leaves less room for execution misses.
The central question is whether High-Value Product demand, margin expansion and a higher 2026 outlook can support further gains after the recent run.
Image Source: Zacks Investment Research
WST's HVP Mix Supports the Rally
High-Value Product Components remain West's main growth engine. Second-quarter sales reached $424.1 million, up 19.4% year over year and 18.4% organically, representing 49% of total company sales.
Demand benefited from biologics, GLP-1 elastomers and customer upgrades to higher-quality containment solutions, including Annex 1-related conversions. NovaPure and FluroTec products were key contributors, while High-Value Product Delivery Devices sales increased 29.6% to $131.2 million.
Becton, Dickinson and Company (BDX - Free Report) is investing $110 million to expand U.S. production of prefillable syringes for biologic and GLP-1 drug delivery. AptarGroup, Inc. (ATR - Free Report) , another drug-delivery supplier, reported a 4% increase in Pharma sales in the second quarter, underscoring continued activity across injectable and advanced drug-delivery markets.
West's Q2 Beat Adds Fundamental Support
Second-quarter revenues increased 13.8% to $872.3 million, while organic sales grew 12.7%. Adjusted earnings of $2.37 per share rose 28.8% and beat the Zacks Consensus Estimate by 13.9%.
Proprietary Products revenues climbed 16.6% to $722.6 million. Gross margin expanded 200 basis points to 37.7%, and adjusted operating margin improved 230 basis points to 22.6%, showing the earnings benefit from richer product mix and operating leverage.
WST's Raised Outlook Extends the Growth Case
West raised its 2026 revenue outlook to $3.345 billion-$3.380 billion from $3.295 billion-$3.350 billion. Organic sales are now expected to increase 10%-11%, up from the prior 7%-9% range.
Adjusted earnings guidance rose to $8.85-$9.05 per share from $8.40-$8.75. Management now expects both GLP-1 and non-GLP-1 High-Value Product Components to grow in the high teens organically for the year, supporting continued mix improvement.
West's Premium Valuation Tests Further Upside
WST trades at 37.1X forward 12-month earnings, more than double the Zacks sub-industry's 17.8X multiple. The stock also trades above the Medical sector's 21.2X and the S&P 500's 20.7X.
The multiple is below WST's five-year median of 39.1X, but it still implies that investors are paying a sizable premium for growth and execution. Further appreciation may therefore require continued earnings delivery and sustained High-Value Product momentum.
Image Source: Zacks Investment Research
WST Risks Could Check the Momentum
Standard Products sales increased just 2.4% in the second quarter, while West Vantage revenues rose 2% and only 0.8% organically. West Vantage was also affected by cyber-related production downtime, which pushed some revenues into the second half.
Higher oil and commodity costs remain another pressure point. The July 1 sale of SmartDose 3.5mL also creates a portfolio transition, while the Dublin drug-handling ramp and other operational initiatives add execution risk.
Wrapping Up
WST's recent gain is supported by faster High-Value Product growth, wider margins and a stronger 2026 earnings outlook. Against that, the premium valuation and softer performance in Standard Products and West Vantage raise the threshold for additional upside.
View the Zacks #1 Rank List
Image: Bigstock
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) shares have gained 17.2% in the past three months, ahead of the Zacks Medical sector's 18.9% rise and the S&P 500's 2% advance. The move reflects improving operating momentum, but valuation leaves less room for execution misses.
The central question is whether High-Value Product demand, margin expansion and a higher 2026 outlook can support further gains after the recent run.
Image Source: Zacks Investment Research
WST's HVP Mix Supports the Rally
High-Value Product Components remain West's main growth engine. Second-quarter sales reached $424.1 million, up 19.4% year over year and 18.4% organically, representing 49% of total company sales.
Demand benefited from biologics, GLP-1 elastomers and customer upgrades to higher-quality containment solutions, including Annex 1-related conversions. NovaPure and FluroTec products were key contributors, while High-Value Product Delivery Devices sales increased 29.6% to $131.2 million.
Becton, Dickinson and Company (BDX - Free Report) is investing $110 million to expand U.S. production of prefillable syringes for biologic and GLP-1 drug delivery. AptarGroup, Inc. (ATR - Free Report) , another drug-delivery supplier, reported a 4% increase in Pharma sales in the second quarter, underscoring continued activity across injectable and advanced drug-delivery markets.
West's Q2 Beat Adds Fundamental Support
Second-quarter revenues increased 13.8% to $872.3 million, while organic sales grew 12.7%. Adjusted earnings of $2.37 per share rose 28.8% and beat the Zacks Consensus Estimate by 13.9%.
Proprietary Products revenues climbed 16.6% to $722.6 million. Gross margin expanded 200 basis points to 37.7%, and adjusted operating margin improved 230 basis points to 22.6%, showing the earnings benefit from richer product mix and operating leverage.
WST's Raised Outlook Extends the Growth Case
West raised its 2026 revenue outlook to $3.345 billion-$3.380 billion from $3.295 billion-$3.350 billion. Organic sales are now expected to increase 10%-11%, up from the prior 7%-9% range.
Adjusted earnings guidance rose to $8.85-$9.05 per share from $8.40-$8.75. Management now expects both GLP-1 and non-GLP-1 High-Value Product Components to grow in the high teens organically for the year, supporting continued mix improvement.
West's Premium Valuation Tests Further Upside
WST trades at 37.1X forward 12-month earnings, more than double the Zacks sub-industry's 17.8X multiple. The stock also trades above the Medical sector's 21.2X and the S&P 500's 20.7X.
The multiple is below WST's five-year median of 39.1X, but it still implies that investors are paying a sizable premium for growth and execution. Further appreciation may therefore require continued earnings delivery and sustained High-Value Product momentum.
Image Source: Zacks Investment Research
WST Risks Could Check the Momentum
Standard Products sales increased just 2.4% in the second quarter, while West Vantage revenues rose 2% and only 0.8% organically. West Vantage was also affected by cyber-related production downtime, which pushed some revenues into the second half.
Higher oil and commodity costs remain another pressure point. The July 1 sale of SmartDose 3.5mL also creates a portfolio transition, while the Dublin drug-handling ramp and other operational initiatives add execution risk.
Wrapping Up
WST's recent gain is supported by faster High-Value Product growth, wider margins and a stronger 2026 earnings outlook. Against that, the premium valuation and softer performance in Standard Products and West Vantage raise the threshold for additional upside.
Currently, West carries a Zacks Rank #3 (Hold). Likewise, Becton, Dickinson and Company, and AptarGroup also carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.